Serveur d'exploration Tocilizumab - Exploration (Accueil)

Index « AbsEn.i » - entrée « cost »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
cosmic < cost < costa  Facettes :

List of bibliographic references indexed by cost

Number of relevant bibliographic references: 128.
[0-20] [0 - 20][0 - 50][20-40]
Ident.Authors (with country if any)Title
000014 (2020) Puja Mehta ; Jessica J. MansonWhat Is the Clinical Relevance of TNF Inhibitor Immunogenicity in the Management of Patients With Rheumatoid Arthritis?
000151 (2020) Joanna Wai Yee Leong [Singapour] ; Peter P. Cheung [Singapour] ; Sajeewani Dissanayake [Singapour] ; Warren Weng Seng Fong [Singapour] ; Keng Hong Leong [Singapour] ; Ying Ying Leung [Singapour] ; Anita Yee Nah Lim [Singapour] ; Nai Lee Lui [Singapour] ; Mona Manghani [Singapour] ; Amelia Santosa [Singapour] ; Melonie Kannamma Sriranganathan [Singapour] ; Ernest Suresh [Singapour] ; Teck Choon Tan [Singapour] ; Gim Gee Teng [Singapour] ; Manjari Lahiri [Singapour]Singapore Chapter of Rheumatologists updated consensus statement on the eligibility for government subsidization of biologic and targeted-synthetic therapy for the treatment of rheumatoid arthritis.
000277 (2020) Sergiu Pasca [Roumanie] ; Ancuta Jurj [Roumanie] ; Bobe Petrushev [Roumanie] ; Ciprian Tomuleasa [Roumanie] ; Daniela Matei [Roumanie]MicroRNA-155 Implication in M1 Polarization and the Impact in Inflammatory Diseases
000459 (2020) Benjamin Birkner [Allemagne] ; Jürgen Rech [Allemagne] ; Tom Stargardt [Allemagne]Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
000460 (2020) Celine J. Van De Laar ; Martijn A H. Oude Voshaar ; Walid K H. Fakhouri [États-Unis] ; Liliana Zaremba-Pechmann [États-Unis] ; Francesco De Leonardis [États-Unis] ; Inmaculada De La Torre [États-Unis] ; Mart A F J. Van De LaarCost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis
000488 (2020) Jennie H. Best [États-Unis] ; Steven C. Vlad [États-Unis] ; Jinglan Pei [États-Unis]Comparative Cost per Response for 4 Clinical Endpoints with Tocilizumab Monotherapy vs Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial (ADACTA) in Patients with Rheumatoid Arthritis
000592 (2020) Jinxin Qi [République populaire de Chine, Canada] ; Chengchao Ding [République populaire de Chine] ; Xian Jiang [République populaire de Chine] ; Yong Gao [Canada, République populaire de Chine]Advances in Developing CAR T-Cell Therapy for HIV Cure
000627 (2019) Maxime Samson [France] ; Hélène Greigert [France] ; Thibault Ghesquière [France] ; Bernard Bonnotte [France][Treatment of giant cell arteritis].
000679 (2019) Dimitrios Daoussis [Grèce] ; Stamatis-Nick Liossis [Grèce]Treatment of systemic sclerosis associated fibrotic manifestations: Current options and future directions.
000694 (2019) Christoph Lohan [Royaume-Uni] ; Alex Diamantopoulos [Royaume-Uni] ; Corinne Lereun [France] ; Emily Wright [Royaume-Uni] ; Natalie Bohm [Royaume-Uni] ; Laura Marie Sawyer [Royaume-Uni]Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation
000809 (2019) Piercarlo Sarzi-Puttini [Italie] ; Angela Ceribelli [Italie] ; Daniela Marotto [Italie] ; Alberto Batticciotto [Italie] ; Fabiola Atzeni [Italie]Systemic rheumatic diseases: From biological agents to small molecules.
000863 (2019) Marie Fournier ; Chieh-I Chen [États-Unis] ; Andreas Kuznik [États-Unis] ; Clare Proudfoot [Royaume-Uni] ; Usha G. Mallya [États-Unis] ; Kaleb Michaud [États-Unis]Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient
000A07 (2019) Diana Brixner [États-Unis] ; Manish Mittal [États-Unis] ; David T. Rubin [États-Unis] ; Philip Mease [États-Unis] ; Harry H. Liu [États-Unis] ; Matthew Davis [États-Unis] ; Arijit Ganguli [États-Unis] ; A Mark Fendrick [États-Unis]Participation in an innovative patient support program reduces prescription abandonment for adalimumab-treated patients in a commercial population
000A34 (2019) Marco Sciveres [Italie] ; Silvia Nastasio [États-Unis] ; Giuseppe Maggiore [Italie]Novel Diagnostic and Therapeutic Strategies in Juvenile Autoimmune Hepatitis
000B78 (2019) Bogdan Batko [Pologne] ; Paulina Rolska-W Jcik [Pologne] ; Magdalena Władysiuk [Pologne]Indirect Costs of Rheumatoid Arthritis Depending on Type of Treatment—A Systematic Literature Review
000C12 (2019) Jie Li ; Jun Bao [République populaire de Chine] ; Jian Zeng [République populaire de Chine] ; Aizhu Yan [République populaire de Chine] ; Chunqiu Zhao [République populaire de Chine] ; Qiang ShuIguratimod: a valuable remedy from the Asia Pacific region for ameliorating autoimmune diseases and protecting bone physiology
000C32 (2019) Peter. C. Taylor [Royaume-Uni] ; Alejandro Balsa Criado ; Anne-Barbara Mongey ; Jerome Avouac ; Hubert Marotte ; Rudiger B. MuellerHow to Get the Most from Methotrexate (MTX) Treatment for Your Rheumatoid Arthritis Patient?—MTX in the Treat-to-Target Strategy
000C47 (2019) Ramya Uppuluri [Inde] ; Meena Sivasankaran [Inde] ; Shivani Patel [Inde] ; Venkateswaran Vellaichamy Swaminathan [Inde] ; Kesavan Melarcode Ramanan [Inde] ; Nikila Ravichandran [Inde] ; Balasubramaniam Ramakrishnan [Inde] ; Indira Jayakumar [Inde] ; Lakshman Vaidhyanathan [Inde] ; Revathi Raj [Inde]Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide for Primary Immune Deficiency Disorders in Children: Challenges and Outcome from a Tertiary Care Center in South India.
000C55 (2019) Cindy Strehl [Allemagne] ; Lisa Ehlers [Allemagne] ; Timo Gaber [Allemagne] ; Frank Buttgereit [Allemagne]Glucocorticoids—All-Rounders Tackling the Versatile Players of the Immune System
000C97 (2019) Josef S. Smolen [Autriche] ; Joao Goncalves [Portugal] ; Mark Quinn [Royaume-Uni] ; Fabrizio Benedetti [Italie] ; Jake Yongkwon LeeEra of biosimilars in rheumatology: reshaping the healthcare environment
000D49 (2019) Noemi Muszbek [Royaume-Uni] ; Clare Proudfoot [Royaume-Uni] ; Marie Fournier [France] ; Chieh-I Chen [États-Unis] ; Andreas Kuznik [États-Unis] ; Zsofia Kiss [Royaume-Uni] ; Peter Gal [Hongrie] ; Kaleb Michaud [États-Unis]Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/AbsEn.i -k "cost" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/AbsEn.i  \
                -Sk "cost" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    cost
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021